We are live on ! Find out more
CODX

Co-Diagnostics

30 hedge funds and large institutions have $940K invested in Co-Diagnostics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more call options, than puts

Call options by funds: $38K | Put options by funds: $5K

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0.18% less ownership

Funds ownership: 0.49%0.3% (-0.18%)

9% less funds holding

Funds holding: 3330 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

51% less capital invested

Capital invested by funds: $1.93M → $940K (-$993K)

Holders
30
Holders Change
-3
Holders Change %
-9.09%
% of All Funds
0.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
8
Reduced
7
Closed
8
Calls
$38K
Puts
$5K
Net Calls
+$33K
Net Calls Change
+$25K

CODX Hedge Fund Activity: Q4 2025 in Review

30 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2025, worth a combined $940K — down 51% from $1.93M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of CODX and 5 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $73.7K. The largest seller was HRT Financial, exiting entirely with an estimated $51K sold.

  • 30 institutional investors held Co-Diagnostics (CODX) as of Q4 2025, down from 33 in Q3 2025.
  • Funds reported $940K of Co-Diagnostics stock for Q4 2025, down 51% quarter-over-quarter.
  • 5 funds opened new Co-Diagnostics positions in Q4 2025 and 8 closed out, a net change of -3 holders.
  • The largest Co-Diagnostics buyer in Q4 2025 was Vanguard Group, an estimated $73.7K added.
  • The largest Co-Diagnostics seller in Q4 2025 was HRT Financial, an estimated $51K sold.

Based on aggregated 13F filings for Q4 2025.